Exodus Point Capital Management, LP Vir Biotechnology, Inc. Transaction History

Exodus Point Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$8.6 - $11.9 $408,388 - $565,095	-47,487 Reduced 58.56%	33,607 $340,000
Q3 2023 Nov 09, 2023	BUY	$9.14 - $24.62 $573,260 - $1.54 Million	62,720 Added 341.35%	81,094 $760,000
Q2 2023 Aug 10, 2023	SELL	$23.2 - $27.29 $476,017 - $559,936	-20,518 Reduced 52.76%	18,374 $451,000
Q1 2023 May 11, 2023	BUY	$22.26 - $30.85 $328,713 - $455,561	14,767 Added 61.21%	38,892 $905,000
Q4 2022 Feb 13, 2023	SELL	$19.96 - $28.22 $304,250 - $430,157	-15,243 Reduced 38.72%	24,125 $611,000
Q3 2022 Nov 10, 2022	SELL	$18.26 - $31.1 $102,256 - $174,160	-5,600 Reduced 12.45%	39,368 $759,000
Q2 2022 Aug 19, 2022	SELL	$19.08 - $26.7 $235,809 - $329,985	-12,359 Reduced 21.56%	44,968 $1.15 Million
Q1 2022 May 13, 2022	BUY	$21.19 - $40.01 $1.21 Million - $2.29 Million	57,327 New	57,327 $1.47 Million
Q2 2021 Aug 16, 2021	SELL	$38.75 - $51.0 $728,112 - $958,290	-18,790 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$26.34 - $83.07 $494,928 - $1.56 Million	18,790 New	18,790 $963,000

219

87.4M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $1.04B
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.